Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ALDR

Alder Biopharmaceuticals (ALDR) Stock Price, News & Analysis

Alder Biopharmaceuticals logo

About Alder Biopharmaceuticals Stock (NASDAQ:ALDR)

Key Stats

Today's Range
$18.88
$18.88
50-Day Range
$18.88
$18.88
52-Week Range
$8.39
$19.12
Volume
N/A
Average Volume
5.12 million shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Receive ALDR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alder Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALDR Stock News Headlines

The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
See More Headlines

ALDR Stock Analysis - Frequently Asked Questions

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.05) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alder Biopharmaceuticals investors own include Bristol-Myers Squibb (BMY), (CPXX) (CPXX), NVIDIA (NVDA), Celldex Therapeutics (CLDX), Meta Platforms (META), Gilead Sciences (GILD) and Micron Technology (MU).

Company Calendar

Last Earnings
8/07/2018
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALDR
Fax
N/A
Employees
202
Year Founded
N/A

Profitability

Net Income
$-296,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.62 million
Book Value
$1.61 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.58 billion
Optionable
Optionable
Beta
2.64
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:ALDR) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners